Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Virtual Conference
Trevi Therapeutics (Nasdaq: TRVI) announced that its management will present at the 2020 BMO Capital Markets Prescriptions for Success Healthcare Conference on June 23, 2020, at 11:30 a.m. ET. The event will include a virtual fireside chat and investor meetings. The company focuses on developing nalbuphine ER for treating serious conditions such as chronic pruritus and cough related to idiopathic pulmonary fibrosis. An archived webcast of the presentation will be available on the company's website for 30 days post-conference.
- None.
- None.
NEW HAVEN, Conn., June 17, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that management will present via a virtual fireside chat, as well as host virtual investor meetings, at the 2020 BMO Capital Markets Prescriptions for Success Healthcare Conference on June 23, 2020:
Presentation Time: 11:30 a.m. ET
A live webcast of the virtual fireside chat can be accessed by visiting ‘News & Events’ in the ‘Investors & News’ section on the Company’s website at www.trevitherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company’s website following the conference.
The Company’s corporate presentation is posted to its website in the ‘Investors & News’ section under ‘News & Events’.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.
Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.
About Nalbuphine ER
Nalbuphine ER is an oral extended release formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The ĸ- and µ-opioid receptors are known to be critical mediators of itch, cough and certain movement disorders. Nalbuphine’s mechanism of action also mitigates the risk of abuse associated with µ-opioid agonists because it antagonizes, or blocks, µ-opioid receptors. Nalbuphine is currently the only opioid approved for marketing that is not classified as a controlled substance in the United States and most of Europe.
Investor Contact
Chris Seiter, Chief Financial Officer
Trevi Therapeutics, Inc.
chris.seiter@trevitherapeutics.com
203-304-2499
Media Contact
Rosalia Scampoli
rscampoli@marketcompr.com
914-815-1465
FAQ
What is Trevi Therapeutics presenting at the BMO Capital Markets Conference on June 23, 2020?
What time is Trevi Therapeutics' presentation at the conference?
How can I access Trevi Therapeutics' presentation webcast?
What is nalbuphine ER developed by Trevi Therapeutics used for?
What clinical trial is Trevi Therapeutics currently conducting?
